RESEARCH ARTICLE

MRTF-A promotes angiotensin II-induced inflammatory response and aortic dissection in mice

Sohei Ito1, Yohei Hashimoto1, Ryohei Majima1, Eichi Nakao1, Hiroki Aoki2*, Michihide Nishihara1, Satoko Ohno-Urabe1, Aya Furusho1, Saki Hirakata1, Norifumi Nishida1, Makiko Hayashi1, Koichiro Kuwahara3, Yoshihiro Fukimoto1

1 Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan, 2 Cardiovascular Research Institute, Kurume University, Kurume, Japan, 3 Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan

* haoki@med.kurume-u.ac.jp

Abstract

Aortic dissection (AD) is a major cause of acute aortic syndrome with high mortality due to the destruction of aortic walls. Although recent studies indicate the critical role of inflammation in the disease mechanism of AD, it is unclear how inflammatory response is initiated. Here, we demonstrate that myocardin-related transcription factor A (MRTF-A), a signal transducer of humoral and mechanical stress, plays an important role in pathogenesis of AD in a mouse model. A mouse model of AD was created by continuous infusion of angiotensin II (AngII) that induced MRTF-A expression and caused AD in 4 days. Systemic deletion of Mrtfa gene resulted in a marked suppression of AD development. Transcriptome and gene annotation enrichment analyses revealed that AngII infusion for 1 day caused pro-inflammatory and pro-apoptotic responses before AD development, which were suppressed by Mrtfa deletion. AngII infusion for 1 day induced pro-inflammatory response, as demonstrated by expressions of Il6, Tnf, and Ccl2, and apoptosis of aortic wall cells, as detected by TUNEL staining, in an MRTF-A-dependent manner. Pharmacological inhibition of MRTF-A by CCG-203971 during AngII infusion partially suppressed AD phenotype, indicating that acute suppression of MRTF-A is effective in preventing the aortic wall destruction. These results indicate that MRTF-A transduces the stress of AngII challenge to the pro-inflammatory and pro-apoptotic responses, ultimately leading to AD development. Intervening this pathway may represent a potential therapeutic strategy.

Introduction

Aortic dissection (AD) is a serious aortic disease which often results in a lethal outcome [1]. Although establishing preventive and therapeutic strategies is an urgent issue for AD, it is hampered by the elusive molecular pathogenesis of AD. Several genetic disorders are known to predispose individuals to aortic aneurysm and AD [2]. The best characterized genetic disorders for familial AD are mutation of FBN1 that causes Marfan syndrome, and mutations of
TGFB2, TGFBR1, TGFBR2 and SMAD3 that cause Loeys-Dietz syndrome, underscoring the importance of TGF-β pathway for the homeostasis of aortic walls. Another group of culprit genes for familial AD are those encoding contractile proteins in smooth muscle cells (SMCs), including smooth muscle α-actin (ACTA2), myosin heavy chain (MYH11), and those encoding the regulators of SMC contraction, including myosin light chain (MYLK) and cyclic GMP-dependent protein kinase (PRKG), indicating the importance of SMC cytoskeleton in pathogenesis of AD. Currently it is unclear how abnormalities in SMC cytoskeletal proteins result in AD development.

Studies in human AD samples and animal AD models indicate that inflammatory response plays a central role in the pathogenesis of AD [3, 4]. We also reported the involvement of inflammatory response in mouse models [5–7] and in human AD tissue [8]. Although these studies demonstrated the importance of inflammation, it remains elusive how inflammatory response is initiated or whether and how it is related to SMC cytoskeleton.

Recently, myocardin-related transcription factor (MRTF) cofactors were proposed to transduce neurohumoral and mechanical stimuli to stress response [9]. Specifically, neurohumoral and mechanical stimuli to cells promote Rho family GTPases-dependent actin polymerization that liberates MRTF to enter the nuclei and activate serum response factor (SRF)-dependent gene expression [9]. A series of studies have shown that MRTF-A, a member of MRTF family, regulates cardiovascular inflammation and remodeling in response to mechanical and humoral stimuli [10–12]. Therefore, MRTF-A is an attractive candidate that links insults on aortic wall, actin cytoskeleton, and inflammatory response in the context of AD pathogenesis. Current study was designed to test if MRTF-A is involved in the molecular pathogenesis of AD, using angiotensin II-induced mouse model of AD [13] with genetic deletion [11] or pharmacological inhibition [14] of MRTF-A.

Materials & methods

Animal experiments

All animal experimental protocols were approved by the Animal Experiments Review Boards of Kurume University. Mice with genetic deletion of Mrtfa (MRTF-A-KO) was created as previously described [11] and backcrossed to C57BL6/J for more than 5 generations. All animal experiments were done in male mice at the age of 10–11 weeks, as AD predominantly affects men [15]. C57BL/6J mice were purchased from Charles River Laboratories. We used wild type (WT) C57BL/6J mouse as a control for MRTF-A-KO mouse to facilitate the experiments and minimize the number of mice to sacrifice, because the reproductivity of MRTF-A-KO line was low in our hands. Angiotensin II (AngII, 1 μg/kg/min, Peptide Institute #4001, Osaka, Japan) was subcutaneously infused using osmotic minipumps (Durect Alzet #1007D, Cupertino, CA) for 4 days. Implantation of the minipumps filled with saline did not cause discernible aortopathy (S1 Fig). Mice were administered twice daily with 300 mg/kg CCG-203971 (Cayman Chemical #15075, Ann Arbor, MI) in 50 μL dimethylsulfoxide (DMSO) or 50 μL DMSO alone. Administration of CCG-203971 or DMSO was started 12 hours before starting AngII infusion and continued throughout the observational period. Systolic blood pressure was measured by the tail-cuff method (BP-98A, Softron, Tokyo, Japan).

At the end of experimental periods, mice were killed by pentobarbital overdose. For the histological analysis, we excised aortae 4 days after AngII infusion. For the expression analysis we obtained aortae with or without 1 day AngII infusion. The aortic samples were obtained after phosphate-buffered saline (PBS) perfusion at the physiological pressure from the root of aorta to just bellow subclavian artery branch, frozen in liquid nitrogen, and stored at -80˚C until analysis. We used 4% paraformaldehyde in PBS for histological analysis. For the expression
analysis, perfusion was performed with PBS. For quantification of the tear area, 200 μl of 1% Evans blue solution was administered from orbital venous plexus before pentobarbital overdose, followed by PBS perfusion to wash out excessive Evans blue.

**Quantification of area of tear and hematoma**

Excised aortae was opened, pinned and photographed under natural light and 488 nm excitation light to obtain the fluoresce of Evans blue. We measured the area of tear and hematoma using Image-Pro PLUS software version 6 (Media Cybernetics, Rockville, MD, USA). We also measure the area of the ascending aorta defined as an area from the root of aorta to just hellow subclavian artery branch.

We defined aortic dissection (AD) as the lesion with the intramural hematoma connected to the intimal tear. When the intimal tear was visualized by Evans blue perfusion, intramural hematoma was always associated with the intimal tear. Our collaborators also reported that the intramural hematoma in this model was associated with the disruption of intima-media elastic lamellae by propagation-based phase-contrast synchrotron imaging [16]. As for the incidence of AD, the presence of AD was determined by the presence of intramural hematoma in the macroscopic images.

**Expression analysis**

For protein and mRNA expression analysis, aortic samples were pulverized using SK Mill (Tokken, Kashiwa, Japan), and the proteins were extracted with RIPA buffer. After resolving the proteins using the NuPAGE electrophoresis system (Invitrogen, Carlsbad, CA), western blotting was performed using antibodies to Myc (0.5 μg/mL, Cell Signaling Technology #9402, Danvers, MA), Stat3 (0.5 μg/mL, Cell Signaling Technology #12648), phospho-Stat3 (P-Tyr705, 0.5 μg/mL, Cell Signaling Technology #9145), MRTF-A (0.56 μg/mL, Proteintech #21166-1-AP, Rosemont, IL) and Gapdh (0.2 μg/mL, Merck Millipore #MAB374, Temecula, CA). As we noticed in preliminary study that protein expression levels were highly variable within a experimental group, we used 16 to 18 samples in a given group for western blotting. Images of whole membranes are shown in S2 Fig.

For mRNA expression analysis, we used RNeasy kit (Qiagen, Hilden, Germany) to isolate total RNA. We performed transcriptome analysis using the SurePrint G3 Mouse Gene Expression v2 8x60K Microarray Kit (Agilent, Santa Clara, CA). The full dataset of the transcriptome analysis is available at Gene Expression Omnibus (accession # GSE138484). We performed the gene annotation enrichment analysis for the selected genes using Database for Annotation, Visualization and Integrated Discovery (DAVID) [17] with the Gene Ontology terms set to GOTERM_BP_FAT, GOTERM_CC_FAT and GOTERM_MF_FAT. The full lists of the DAVID analysis and corresponding gene descriptions are available as S1 and S2 Tables.

mRNA expressions of *Il6, Ccl2, Tnf* and *Actb* were measured by quantitative real time polymerase chain reaction (qRT-PCR) using commercially available probes (primer set ID MA104898, MA108953, MA163499, MA050368: Takara Bio, Shiga, Japan).

**Histological analysis**

We observed 5 μm sections of paraffin-embedded ascending aortic tissue with elastic van Gieson (EVG) or hematoxylin and eosin (H&E) staining. The tissue sections were also stained for MRTF-A (3.3 μg/mL, NOVUS Biologicals #NBP1-1968, Centennial, CO) with TSA-plus system (Perkin Elmer, Waltham, MA), smooth muscle α-actin (SMA, 0.2 μg/mL, Sigma-Aldrich, St Louis, MO) with Dylight 549-labeled secondary antibody (1:100, antibody concentration undetermined, Jackson ImmunoResearch #115-505-166, West Grove, PA),
Cd31 (1.67 μg/mL, Abcam #ab56299, Cambridge, UK) with Cy3 conjugated secondary antibody (15 μg/mL, Jackson ImmunoResearch #712-165-153), Il6 (1:300, antibody concentration undetermined, Abcam #ab6672) with Cy3 conjugated secondary antibody and Myc (1 μg/mL, Cell Signaling Technology #9402) with Cy3 conjugated secondary antibody. Frozen ascending aortic tissue sections were stained for Cd45 (0.5 μg/mL, Biolegend #103101, San Diego, CA) with Cy3 conjugated secondary antibody. Isotype control antibodies were used for rabbit IgG (Abcam #ab37415) and Rat IgG2b kappa (Abcam #ab18541) at the same concentrations as the corresponding antibodies. For terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, we used in situ Apoptosis Detection Kit (Takara Bio #MK500) with protease K (Takara Bio #9034) for antigen retrieval. Nuclei were stained with 4’,6-diamidino-2-phenylindole mounting media (DAPI, Vector Laboratories #H-1500, Burlingame, CA).
Statistical analysis

All data are expressed as medians and interquartile ranges using box plots. Statistical analysis was performed with Mann-Whitney test for the comparisons of 2 groups. Kruskal-Wallis test was performed for multiple groups. Post-test analysis was performed by Dunn’s multiple-comparison test. P < 0.05 was considered significant.

Results

Role of MRTF-A in AngII-induced AD

We administered AngII (1 μg/kg/min) to WT mice that caused ascending aortic dissection (AD) in 4 days after AngII infusion (Fig 1A) without significant changes in systolic blood pressure (Fig 1B), as previously reported [18]. Our collaborators have demonstrated that this AD model is characterized by the progressive disruption of intima-medial elastic lamellae that is associated with the intramural hematoma by three dimensional imaging [16]. Consistently, our histological observation showed intramural hematomas and tears defined as disruption of elastic lamella at 4 days of AngII infusion (Fig 1C). For the quantitative analysis of AD, we measured the areas of intramural hematoma and intimal tear in the ascending aorta as visualized by Evans blue perfusion (Fig 1D).

To evaluate the localization of MRTF-A in mouse aorta, we performed immunofluorescence staining for MRTF-A and smooth muscle α-actin (SMA), a marker of smooth muscle cells (Fig 2A). MRTF-A staining was detected mainly in the medial layer and overlapped with part of SMA-positive smooth muscle cells in the aortic wall. AngII infusion induced MRTF-A protein expression mainly in the medial layer as demonstrated by immunofluorescence staining (Fig 2B). AngII-induced increase in MRTF-A expression was confirmed by western blotting (Fig 2C). To clarify the role of MRTF-A in AD model, we compared the AD phenotype in WT mice and MRTF-A knockout (MRTF-A-KO) mice (Fig 2D, Table 1). The incidence of AD in MRTF-A-KO mice (0.0%, n = 9) was significantly lower compared to WT mice (55.6%, n = 18; p < 0.05). Quantitative analysis of hematoma and tear areas also demonstrated the significant suppression of AD phenotype in MRTF-A-KO mice (Fig 2E).

Table 1. Incidence of AD in mouse model.

| Genotype | WT AngII + DMSO | KO AngII + DMSO | WT AngII + CCG |
|----------|-----------------|-----------------|----------------|
| Total (n)| 18              | 9               | 8              |
| AD (n)   | 10              | 0               | 2              |
| AD (%)   | 55.6            | 0.0 **          | 25.0           |

The incidence of AD is shown for each experimental group.

** P < 0.01 compared with WT (AngII + DMSO) by Fisher’s exact test.
A

Control

WT (3) KO (3)

AngII

WT (3) KO (3)

C3

C4

C1

C2

Color Key

-2 -1 0 1 2

Distance from Median

B

C1 up

C4 up 3

C4 down 551

5,500

C1 down

C4 up 235

C4 down 1

488

C

C3 up

C4 up 61

C4 down 27

262

C3 down

C4 up 2

C4 down 28

114
To clarify the role of MRTF-A in AngII-induced aortic pathology, we performed transcriptome analysis of aortic tissues from WT and MRTF-A-KO mice with and without AngII. We performed the analysis at the first day of AngII administration before AD development to avoid the consequence of the catastrophic aortic wall destruction due to AD. We defined AD-related genes as those with significant changes by AngII ($P < 0.05$, fold change $> 2$ or $< 0.5$). Among the AD-related genes, we further defined MRTF-A-regulate genes, as those with significant changes between WT and MRTF-A-KO (Fig 3A). Within the AngII-sensitive genes, approximately 6,000 genes were upregulated and 700 genes were downregulated (Fig 3B). The effect of $\text{Mrtfa}$ deletion was a partial suppression of the AngII-induced changes. In the absence of AngII challenge, approximately 350 genes were upregulated and 250 genes were downregulated by $\text{Mrtfa}$ deletion (Fig 3C). These findings suggested that MRTF-A mediated part of AngII-induced changes in gene expression. We performed the gene annotation enrichment analysis for the selected genes using Database for Annotation, Visualization and Integrated Discovery (DAVID) [17]. The DAVID analysis revealed that AngII-induced, MRTF-A-dependent genes were highly enriched for inflammatory response, angiogenesis and cell death (Table 2). AngII-suppressed, MRTF-dependent genes were enriched for myofibril and muscle organ development (Table 3), although the enrichment scores were not as high as the AngII-induced genes.

As the transcriptome analysis suggested that MRTF-A regulates the inflammatory response that plays a central role in AD pathogenesis [3, 4], we performed quantitative analysis of inflammatory cytokines by qRT-PCR in aortic tissue (Fig 4). The mRNA expressions of $\text{Il6}$ and $\text{Ccl2}$ were induced by 1 day of AngII infusion in WT aorta, while this response was not observed in MRTF-A-KO mice (Fig 4A). AngII challenge did not significantly alter $\text{Tnf}$ expression, although MRTF-A-KO aorta showed lower $\text{Tnf}$ expression in the presence of AngII. AngII-induced and MRTF-A-dependent inflammatory response was also demonstrated at the protein level by the western blotting for activated (phosphorylated) Stat3 (Fig 4B and 4C). At the tissue level, infiltration of CD45-positive inflammatory cells was demonstrated near the site of intimal tear at day 4 of AngII infusion (Fig 4D).

We next focused on apoptosis that may participate in AD pathogenesis [19]. We performed TUNEL staining to detect the double strand break of DNA, a marker of apoptotic cells, in WT or MRTF-A-KO aorta before, 1 day and 4 days after AngII infusion (Fig 5A). TUNEL-positive cells were not observed in either WT or MRTF-A-KO aortic tissue before AngII infusion. WT aortic tissue exhibited TUNEL-positive cells in the intimal and medial layers at day 1, and at the site of intimal tear at day 4 of AngII infusion, whereas MRTF-A-KO aorta did not. Double fluorescence labeling with cell type markers revealed the TUNEL staining colocalized with endothelial cell marker Cd31 and smooth muscle cell marker SMA (Fig 5B).
To better characterize the MRTF-A-dependent inflammation and apoptosis, we examined the protein expression of Myc, a well-characterized regulator of apoptosis [20], as Myc mRNA expression was induced by AngII in an MRTF-A-dependent manner in our transcriptome analysis. Western blotting revealed that Myc protein was induced by AngII infusion in WT aorta, and to the lesser extent in MRTF-A-KO aorta (Fig 6A and 6B), suggesting that Myc induction by AngII was partly mediated by MRTF-A. Double fluorescence labeling revealed the colocalization of TUNEL staining and Myc expression (Fig 6C), consistent with the notion

| Annotation Cluster 1 (18.28) | Annotation Cluster 10 (6.33) |
|-------------------------------|-------------------------------|
| inflammatory response         | blood vessel morphogenesis    |
| defense response              | Angiogenesis                  |
| immune response               | vasculature development       |
| Annotated Cluster 2 (16.15)   | Annotated Cluster 11 (5.73)   |
| response to cytokine          | leukocyte chemotaxis          |
| cellular response to cytokine stimulus | positive regulation of leukocyte migration |
| cytokine-mediated signaling pathway | chemokine-mediated signaling pathway |
| Annotated Cluster 3 (11.13)   | Annotated Cluster 12 (5.44)   |
| leukocyte migration           | cytokine biosynthetic process |
| cell chemotaxis               | cytokine metabolic process    |
| leukocyte chemotaxis          | regulation of cytokine biosynthetic process |
| Annotated Cluster 4 (10.82)   | Annotated Cluster 13 (5.43)   |
| defense response              | cell activation               |
| response to external stimulus | leukocyte activation          |
| response to biotic stimulus   | Hemopoiesis                   |
| Annotated Cluster 5 (9.24)    | Annotated Cluster 14 (5.37)   |
| regulation of cell proliferation | apoptotic process             |
| cell proliferation            | cell death                    |
| positive regulation of cell proliferation | programmed cell death |
| Annotated Cluster 6 (7.46)    | Annotated Cluster 15 (5.30)   |
| immune effector process       | positive regulation of tumor necrosis factor superfamily cytokine production |
| regulation of immune response | positive regulation of tumor necrosis factor production |
| leukocyte mediated immunity   | regulation of tumor necrosis factor superfamily cytokine production |
| Annotated Cluster 7 (7.16)    | Annotated Cluster 16 (5.20)   |
| regulation of chemokine production | regulation of cell communication         |
| chemokine production          | regulation of signaling        |
| positive regulation of chemokine production | regulation of signal transduction |
| Annotated Cluster 8 (7.06)    | Annotated Cluster 17 (5.12)   |
| cytokine production           | myeloid leukocyte activation   |
| regulation of cytokine production | regulation of leukocyte mediated immunity |
| positive regulation of cytokine production | regulation of myeloid leukocyte mediated immunity |
| Annotated Cluster 9 (6.69)    |                               |
| Hemopoiesis                   |                               |
| leukocyte differentiation     |                               |
| immune system development     |                               |

Gene annotation enrichment analysis was performed for the genes with lower expression in MRTF-A-KO aorta compared to wild-type (WT) aorta, among the AngII-induced genes.

https://doi.org/10.1371/journal.pone.0229888.t002

To better characterize the MRTF-A-dependent inflammation and apoptosis, we examined the protein expression of Myc, a well-characterized regulator of apoptosis [20], as Myc mRNA expression was induced by AngII in an MRTF-A-dependent manner in our transcriptome analysis. Western blotting revealed that Myc protein was induced by AngII infusion in WT aorta, and to the lesser extent in MRTF-A-KO aorta (Fig 6A and 6B), suggesting that Myc induction by AngII was partly mediated by MRTF-A. Double fluorescence labeling revealed the colocalization of TUNEL staining and Myc expression (Fig 6C), consistent with the notion
that Myc regulates apoptosis pathway [20]. Tissue localization of TUNEL positive cells in the aortic medial layer was closely correlated with the Il6 expression in the adventitial layer (Fig 6D).

Pharmacological MRTF-A inhibition in AD

The results thus far indicated that MRTF-A promotes AD development. Recently, CCG-203971, a specific inhibitor of MRTF-A-dependent transcription [14], has been reported to prevent the adverse tissue remodeling during inflammatory conditions [21]. To test the effect of the acute MRTF-A inhibition and to explore the clinical implication of our findings, we examined the effect of pharmacological MRTF-A inhibition on the AD model by treating WT mice with CCG-203971. The difference in the prevalence of AD between CCG-203971-treated group and vehicle-treated group did not reach statistical significance (Fig 7A, Table 1). CCG-203971 significantly suppressed the area of intramural hematoma by AD, whereas its effect on the tear area did not reach statistical significance (Fig 7B). AngII infusion caused induction of Il6 and Ccl2, which was not observed in mice treated with CCG-203971 (Fig 7C). On the other hand, CCG-203971 did not significantly alter the appearance of TUNEL-positive cells at day 1 of AngII infusion (Fig 7D). These results indicated that pharmacological inhibition of MRTF-A by CCG-203971 partially suppressed AD phenotype.

Discussion

The main finding in this study was that MRTF-A mediates inflammatory and apoptotic responses, and promotes AD development by AngII challenge. The inflammatory and apoptotic responses occurred at day 1, as indicated by the gene expression and histological analyses. Because the appearance of aortic wall tear, as detected by the Evans blue perfusion, occurred at day 4 of AngII infusion, inflammatory and apoptotic responses likely precede AD development. The involvement of MRTF-A in AD pathogenesis was further supported by the fact that CCG-203971, an inhibitor of MRTF-A, prevented the AngII-induced AD development. As recent studies indicated the involvement of inflammatory response [5, 6, 22, 23] and apoptosis [19, 24] in AD pathogenesis, these data suggested that MRTF-A promotes AD by regulating inflammatory and apoptotic responses.

| Annotation Cluster 1 (2.72) |
|-----------------------------|
| contractile fiber part      |
| Myofibril                   |
| contractile fiber           |

| Annotation Cluster 2 (2.21) |
|-----------------------------|
| muscle organ development    |
| skeletal muscle tissue      |
| development                |
| skeletal muscle organ       |
| development                |

| Annotation Cluster 3 (2.08) |
|-----------------------------|
| alkali metal ion binding    |
| T-tubule                    |
| Sarcolemma                  |

Gene annotation enrichment analysis was performed for the genes with higher expression in MRTF-A-KO aorta compared to wild-type (WT) aorta, among the AngII-suppressed genes.

https://doi.org/10.1371/journal.pone.0229888.t003

Table 3. Up-regulated annotation clusters in MRTF-A-KO.
Fig 4. Inflammatory response in mouse AD model. (A) mRNA expressions were examined by qRT-PCR for Il6, Tnf and Ccl2, and normalized by Actb. The samples were obtained from WT or MRTF-A-KO mice with or without AngII administration for 1 day. (B, C) Protein expressions were examined by western
Proinflammatory molecules, including secreted cytokines and chemokines, and intracellular signaling molecules including Stat3 and NFκB play critical roles in AD pathogenesis [4–6, 23, 25]. These molecules are activated by, and regulate the expression of cytokines such as Il6 and chemokines such as Ccl2 to orchestrate the behavior of resident cells including smooth muscle cells and infiltrating inflammatory cells [5, 23, 26]. Consistent with this notion, we found MRTF-A regulate expression of Il6 and Ccl2, and infiltration of Cd45-positive inflammatory cells in the AD model. On the other hand, a previous report described that Cd45-positive cells appeared only sparsely at the late stage of AngII-induced aortopathy [18]. This apparent discrepancy may be explained by the fact that we observed specifically at the site of intimal tear whereas the previous report seems to show the aortic tissue without apparent tear. These findings suggest that spacio-temporal analysis of cellular dynamics would be required to understand the molecular pathogenesis of AD.

Apoptosis of aortic cells, mainly SMCs, is observed both in human AD and mouse model of AD [24], and tightly coupled with the phenotype of AD in mouse model [19, 27, 28]. Causative involvement of apoptosis in aortopathy was demonstrate by the suppression of SMC apoptosis and thoracic aortic aneurysm by a caspase inhibitor in a mouse model of Marfan syndrome [29]. These findings support the notion that pro-inflammatory and pro-apoptotic responses are the central biological process in pathogenesis of AD. Consistent with this notion, we observed TUNEL-positive apoptotic cells in aortic media appeared at the same time with adventitial expression of Il6. On the other hand, while the localizations of apoptotic cells and Il6 expression were close to each other, they did not overlap. Therefore, a molecular and cellular network is likely to underlie the manifestation of apoptosis and inflammation as a stress response in AD pathogenesis [19]. The findings we obtained by MRTF-A inhibition suggest that pro-inflammatory and pro-apoptotic function is the basis of the MRTF-A-mediated AD development.

The role of MRTF-A in adverse cardiovascular remodeling is consistent with previous reports [10–12, 30]. Mechanistically, MRTF-A is regulated by dynamics of actin cytoskeleton [31] to transduce neurohumoral and mechanical stimuli to the stress response [12]. In this regard, it is noteworthy that genetic abnormalities of SMC cytoskeletal and contractile proteins predispose the patients to AD [32]. Although it is unclear how mutations in cytoskeletal and contractile protein genes lead to AD development, current results suggest that abnormality in actin-dependent regulation of MRTF-A might be one of the mechanisms for the AD susceptibility.

The biological process under the control of MRTF-A seems context-dependent. MRTF-A is reported to mediate pro-inflammatory signal in various cell types including vascular SMCs [10], macrophages [33], and glomerular mesangial cells [34]. In the context of diseases, MRTF-A is pro-inflammatory in atherosclerosis [11, 35], liver injury [36], and inflammatory bowel disease [37]. On the other hand, MRTF-A exerts anti-inflammatory effect in pulmonary arterial SMCs [38]. MRTF-A is neuroprotective in ischemic cerebral injury possibly by inhibiting neuronal apoptosis [39, 40]. MRTF-A also prevents myocardial cell apoptosis [41]. Within the context of anticancer drug doxorubicin effect, MRTF-A can either cell-protective [42] or cell-toxic [43]. Of note, MRTF-A promotes atherogenesis by promoting macrophage survival and proliferation, and inflammatory response [35], exemplifying the complex role of MRTF-A and the relationship between inflammation and apoptosis.
Fig 5. Apoptosis in mouse AD model. (A) Representative histological images are shown with TUNEL and EVG staining. The samples are from WT or MRTF-A-KO mice before (Control) and 1–4 days after starting AngII administration. White arrowheads indicate TUNEL-positive cells. Black arrowheads indicate the tear. (B) Immunofluorescence staining for Cd31, SMA, TUNEL and DAPI on ascending aortae are shown from WT mice 1 day after AngII administration. White arrowheads indicate TUNEL-positive nuclei. Bars 0.1 mm.

https://doi.org/10.1371/journal.pone.0229888.g005
Fig 6. Myc and apoptosis in mouse AD tissue. (A, B) Protein expressions are shown by western blotting for Myc and Gapdh. Representative images (A) and quantitative analysis (B) are shown using ascending aortae from WT or MRTF-A-KO mice with or without AngII administration for 1 day. The numbers in parenthesis indicate the number of biological replicates. * P < 0.05, *** P < 0.001 compared with WT control. (C) Fluorescence staining for Myc, TUNEL, and DAPI on ascending aorta are shown from WT mice 1 day after AngII administration. (D) Fluorescence stainings are shown for Il6 and TUNEL in mouse aorta 1 day after starting AngII administration. Staining with rabbit IgG isotype control (IC) is also shown. White rectangles correspond to the magnified images at the bottom of the panels. Bar 0.1 mm.

https://doi.org/10.1371/journal.pone.0229888.g006
Fig 7. Pharmacological inhibitor of MRTF-A suppressed aortic dissection. Hematomas and tears in the ascending aorta from WT mice with vehicle (DMSO) or CCG-203971 treatment 4 days after starting AngII infusion. Representative images (A) and quantitative analysis for the hematoma and the tear (B) are shown. Bar 1 mm. Red and blue bars indicate the medians and interquartile ranges, respectively. (C) mRNA expressions were examined by qRT-PCR for Il6, Tnf and Ccl2, and normalized by Actb. The samples were obtained from WT with AngII administration for 1 day with or without CCG-203971 treatment. The numbers in parenthesis indicate the number of biological replicates. * P < 0.05. *** P < 0.001. N.S. not significant. (D) TUNEL and DAPI staining of aortic samples with AngII administration for 1 day with or without CCG-203971 treatment. Bar 0.1 mm.

https://doi.org/10.1371/journal.pone.0229888.g007
Our data demonstrated that acute pharmacological inhibition of MRTF-A was effective in preventing AD. This finding suggests that MRTF-A plays an acute role in AD development, probably by promoting inflammation and apoptosis as discussed above. While MRTF-A protein was induced by AngII at day 4, AngII-induced Il6 and Ccl2 expressions were suppressed at day 1 by Mrfα deletion or CCG-203971. Therefore, AngII is likely to activate MRTF-A both at the expression and functional levels. Whether MRTF-A is the trigger of AD initiation or the promoter of AD development awaits further study to delineate the chronological and functional sequence of the molecular events during AD development. Although our findings suggest that MRTF-A inhibition is a potential therapeutic opportunity for AD, the AD-inhibiting effect of CCG-203971 was not as complete as Mrfα deletion. This may be due to the insufficient inhibition of MRTF-A by CCG-203971 during AD development. Alternatively, whole body Mrfα deletion may developmentally alter the function of cells and tissue [44–46], which may affect AD pathogenesis. In addition, prevention of AD in the clinical situation is highly challenging. The annual incidence of AD in the general population is only 6 in 100,000, and prediction of AD is currently difficult, if not impossible [47]. Those who with genetic predisposition to AD, including Marfan syndrome, Loeys-Dietz syndrome and other forms of familial thoracic aortic aneurysm/dissection, may benefit from MRTF-A inhibition for preventing the development of life-threatening AD. However, even for the high risk population of AD, care should be taken for prophylactic chronic MRTF-A inhibition, because the function and its (patho)physiological role of MRTF-A seem context-dependent. Indeed, MRTF-A may play a protective role in neuronal and myocardial ischemia [30, 39, 40, 48, 49]. Another potential opportunity is the acute inhibition of MRTF-A after AD development to prevent further tissue destruction. For the MRTF-A inhibition therapy to realize, the role of MRTF-A needs to be clarified in the context of complex molecular and pathological changes during tissue destruction after AD onset.

In conclusion, our data demonstrated that MRTF-A promoted AD development possibly by activating proinflammatory and proapoptotic pathway. Further study for clarifying the cell type- and disease context-dependent function of MRTF-A would be essential for understanding the pathogenesis of AD, and for the development of preventive, diagnostic and therapeutic strategies for this fatal disease.

Supporting information

S1 Fig. Aortic morphology of mice implanted with saline-filled osmotic minipumps. No obvious aortopathy was observed. Bar 1 mm.

(SIFF)

S2 Fig. Images of western blotting. Images of whole membranes: Membranes are shown for western blotting in Figs 2C, 4B and 6A. Red rectangles indicate the area that were used in corresponding figures. MW; molecular weight marker, LC; loading control. Detection of Myc band: Myc antibody revealed multiple bands in western blotting. True band was determined as the main band in lysate of proliferating smooth muscle cells. Bands with identical molecular weight were also observed in aortic tissue lysate with AngII stimulation, but not in that without AngII. Because Myc was induced by AngII, we concluded that the AngII-dependent bands was a true band of Myc, as indicated by arrowheads.

(TIFF)

S1 Table. Gene annotation enrichment analysis. The table contains Entrez Gene IDs in the comparison groups shown in Fig 3B and 3C, and the results of the gene annotation enrichment analysis.

(XLSX)
S2 Table. Genes in annotation clusters. The table contains Entrez Gene IDs and descriptions of genes in the annotation clusters obtained by the gene annotation enrichment analysis of the comparison groups shown in Fig 3B and 3C. (XLSX)

Acknowledgments
We would like to thank Ms. Kiyohiro, Ms. Nishigata, Ms. Nakao, Ms. Shiramizu, Ms. Nakayama, and Dr. Yamamoto for their technical assistance.

Author Contributions
Conceptualization: Hiroki Aoki, Michihide Nishihara, Satoko Ohno-Urabe, Aya Furusho, Saki Hirakata, Norifumi Nishida, Makiko Hayashi, Koichiro Kuwahara, Yoshihiro Fukumoto.
Data curation: Sohei Ito, Yohei Hashimoto, Ryohei Majima, Eichi Nakao.
Formal analysis: Sohei Ito, Hiroki Aoki, Michihide Nishihara, Satoko Ohno-Urabe, Aya Furusho, Saki Hirakata, Norifumi Nishida, Makiko Hayashi.
Funding acquisition: Hiroki Aoki.
Investigation: Sohei Ito, Yohei Hashimoto, Ryohei Majima, Eichi Nakao, Hiroki Aoki, Michihide Nishihara, Satoko Ohno-Urabe, Aya Furusho, Saki Hirakata, Norifumi Nishida, Makiko Hayashi, Koichiro Kuwahara, Yoshihiro Fukumoto.
Methodology: Sohei Ito.
Project administration: Hiroki Aoki.
Resources: Koichiro Kuwahara.
Supervision: Hiroki Aoki, Koichiro Kuwahara, Yoshihiro Fukumoto.
Writing – original draft: Sohei Ito.
Writing – review & editing: Hiroki Aoki.

References
1. Landenhed M, Engström G, Gottsäter A, Caulfield MP, Hedblad B, Newton-Cheh C, et al. Risk Profiles for Aortic Dissection and Ruptured or Surgically Treated Aneurysms: A Prospective Cohort Study. J Am Heart Assoc. 2015; 4(1):e001513. Epub 2015/01/23. https://doi.org/10.1161/JAHA.114.001513 PMID: 25609416; PubMed Central PMCID: PMC4330075.
2. Pinard A, Jones GT, Milewicz DM. Genetics of Thoracic and Abdominal Aortic Diseases. Circ Res. 2019; 124(4):588–606. Epub 2019/02/15. https://doi.org/10.1161/CIRCRESAHA.118.312436 PMID: 30763214; PubMed Central PMCID: PMC6428422.
3. Cifani N, Proietta M, Tritapepe L, Di Gioia C, Ferri L, Taurino M, et al. Stanford-A acute aortic dissection, inflammation, and metalloproteinases: a review. Ann Med. 2015; 47(6):441–6. Epub 2015/09/05. https://doi.org/10.3109/07853890.2015.1073346 PMID: 26339779.
4. Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res. 2010; 86(2):211–8. Epub 2010/03/06. https://doi.org/10.1093/cvr/cvo076 PMID: 20202975; PubMed Central PMCID: PMC2912657.
5. Ohno-Urabe S, Aoki H, Nishihara M, Furusho A, Hirakata S, Nishida N, et al. Role of Macrophage Socs3 in the Pathogenesis of Aortic Dissection. J Am Heart Assoc. 2018; 7(2):e007389. Epub 2018/01/19. https://doi.org/10.1161/JAHA.117.007389 PMID: 29343476; PubMed Central PMCID: PMC5850160.
6. Son BK, Sawadi D, Tomida S, Fujita D, Aizawa K, Aoki H, et al. Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. Nature communications. 2015; 6:6994. Epub 2015/04/30. https://doi.org/10.1038/ncomms7994 PMID: 25923510.

7. Kimura T, Shiraishi K, Furusho A, Ito S, Hirakata S, Nishida N, et al. Tenasin C protects aorta from acute dissection in mice. Sci Rep. 2014; 4:4051. Epub 2014/02/12. https://doi.org/10.1038/srep04051 PMID: 24514259; PubMed Central PMCID: PMC3920275.

8. Yoshida S, Yamamoto M, Aoki H, Fukuda H, Akasu K, Takagi K, et al. STAT3 Activation Correlates with Adventitial Neutrophil Infiltration in Human Aortic Dissection. Ann Vasc Dis. 2019; 12(2):187–93. Epub 2019/07/06. https://doi.org/10.3400/avd.oa.19-00007 PMID: 31275472; PubMed Central PMCID: PMC6600108.

9. Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motility functions. Nat Rev Mol Cell Biol. 2010; 11(5):353–65. Epub 2010/04/24. https://doi.org/10.1038/nrm2890 PMID: 20414257; PubMed Central PMCID: PMC3073350.

10. Yang Y, Cheng X, Tian W, Zhou B, Wu X, Xu H, et al. MRTF-A steers an epigenetic complex to activate endothelin-induced pro-inflammatory transcription in vascular smooth muscle cells. Nucleic Acids Res. 2014; 42(16):10460–72. Epub 2014/08/28. https://doi.org/10.1093/nar/gku776 PMID: 25159611; PubMed Central PMCID: PMC4176337.

11. Minami T, Kuwahara K, Nakagawa Y, Takaoka M, Kinoshita H, Nakao K, et al. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice. EMBO J. 2012; 31(23):4428–40. Epub 2012/10/30. https://doi.org/10.1002/emboj.2012.296 PMID: 23103763; PubMed Central PMCID: PMC3512386.

12. Kuwahara K, Kinoshita H, Kuwabara Y, Nakagawa Y, Usami S, Minami T, et al. Myocardin-related transcription factor A is a common mediator of mechanical stress- and neurohumoral stimulation-induced cardiac hypertrophic signaling leading to activation of brain natriuretic peptide gene expression. Molecular and cellular biology. 2010; 30(17):4134–48. Epub 2010/07/08. https://doi.org/10.1128/MCB.00154-10 PMID: 20606005; PubMed Central PMCID: PMC2937559.

13. Martin-Alonso M, Garcia-Redondo AB, Guo D, Camafeita E, Martinez F, Alfranca A, et al. Deficiency of MMP17/MT4-MMP proteolytic activity predisposes to aortic aneurysm in mice. Circ Res. 2015; 117(2): e13–26. Epub 2015/05/13. https://doi.org/10.1161/CIRCRESAHA.117.305108 PMID: 25963716.

14. Bell JL, Haak AJ, Wade SM, Kirchoff PD, Neubig RR, Larsen SD. Optimization of novel nippecotic bis (amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett. 2013; 23(13):3826–32. Epub 2013/05/28. https://doi.org/10.1016/j.bmcl.2013.04.080 PMID: 23707258; PubMed Central PMCID: PMC3707396.

15. Nienaber CA, Fattori R, Mehta RH, Richartz BM, Evangelista A, Petzsch M, et al. Gender-related differences in acute aortic dissection. Circulation. 2004; 109(24):2031–41. Epub 2004/06/23. https://doi.org/10.1161/01.CIR. 0000130644.78677.2C PMID: 15197151.

16. Logghe G, Trachet B, Aslanidou L, Villaneuva-Perez P, De Backer J, Stergiopolus N, et al. Propagation-based phase-contrast synchrotron imaging of aortic dissection in mice: from individual elastic lamella to 3D analysis. Sci Rep. 2018; 8(1):2223. Epub 2018/02/06. https://doi.org/10.1038/s41598-018-20673-x PMID: 29396472; PubMed Central PMCID: PMC5797148.

17. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44–57. Epub 2009/01/10. https://doi.org/10.1038/nprot.2008.211 PMID: 19131956.

18. Rateri DL, Davis FM, Balakrishnan A, Howatt DA, Moorlighen JJ, O’Connor WN, et al. Angiotensin II induces region-specific medial disruption during evolution of ascending aortic aneurysms. Am J Pathol. 2014; 184(9):2586–95. Epub 2014/07/20. https://doi.org/10.1016/j.ajpath.2014.05.014 PMID: 25038458; PubMed Central PMCID: PMC4188133.

19. Jia LX, Zhang WM, Zhang HJ, Li TT, Wang YL, Qin YW, et al. Mechanical stretch-induced endoplasmic reticulum stress, apoptosis and inflammation contribute to thoracic aortic aneurysm and dissection. J Pathol. 2015; 236(3):373–83. Epub 2015/03/20. https://doi.org/10.1002/path.4534 PMID: 25788370; PubMed Central PMCID: PMC4029755.

20. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene. 1999; 18(19):2967–87. Epub 1999/ 06/23. https://doi.org/10.1038/sj.onc.1202727 PMID: 10378693.

21. Haak AJ, Tsou PS, Amin MA, Ruth JH, Campbell P, Fox DA, et al. Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther. 2014; 349(3):480–6. Epub 2014/04/08. https://doi.org/10.1124/jpet.114.213520 PMID: 24706986; PubMed Central PMCID: PMC4019321.

22. Anzai A, Shimoda M, Endo J, Kohno T, Katsumata Y, Matsumashi T, et al. Adventitial CXCL1/G-CSF Expression in Response to Acute Aortic Dissection Triggers Local Neutrophil Recruitment and...
Activation Leading to Aortic Rupture. Circ Res. 2015; 116(4):612–23. Epub 2015/01/08. https://doi.org/10.1161/CIRCRESAHA.116.304918 PMID: 25563839.

23. Tieu BC, Lee C, Sun H, Lejeune W, Recinos A 3rd, Ju X, et al. An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest. 2009; 119(12):3637–51. Epub 2009/11/19. https://doi.org/10.1172/JCI38308 PMID: 19920349; PubMed Central PMCID: PMC2786788.

24. Jiang WJ, Ren WH, Liu XJ, Liu Y, Wu FJ, Sun LZ, et al. Disruption of mechanical stress in extracellular matrix is related to Stanford type A aortic dissection through down-regulation of Yes-associated protein. Aging (Albany NY). 2016; 8(9):1923–39. Epub 2016/09/09. https://doi.org/10.18632/aging.101033 PMID: 27608489; PubMed Central PMCID: PMC5076445.

25. Kurihara T, Shimizu-Hirota R, Shimoda M, Adachi T, Shimizu H, Weiss SJ, et al. Neutrophil-derived matrix metalloproteinase 9 triggers acute aortic dissection. Circulation. 2012; 126(25):3070–80. Epub 2012/11/09. https://doi.org/10.1161/CIRCULATIONAHA.112.097097 PMID: 23136157.

26. Hirakata S, Aoki H, Ohno-Urabe S, Nishihara M, Furusho A, Nishida N, et al. Genetic Deletion of Socs3 and Increased Nrf2 Levels. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2016; 38(4):1391–405. Epub 2016/03/30. https://doi.org/10.1080/00009114.2016.1113088.

27. Emrich FC, Okamura H, Datal AR, Penov K, Merk DR, Raaz U, et al. Enhanced caspase activity contributes to aortic wall remodeling and early aneurysm development in a murine model of Marfan syndrome. Arterioscler Thromb Vasc Biol. 2015; 35(1):146–54. Epub 2014/11/02. https://doi.org/10.1161/ATVBAHA.114.304364 PMID: 25359856.

28. Liu W, Wang B, Wang T, Liu X, He X, Liu Y, et al. Ursodeoxycholic Acid Attenuates Acute Aortic Dissection Formation in Angiotsenin II-Infused Apolipoprotein E-Deficient Mice Associated with Reduced ROS and Increased Nrf2 Levels. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2016; 38(4):1391–405. Epub 2016/03/30. https://doi.org/10.1080/00009114.2016.1113088.

29. Small EM, Thatcher JE, Sutherland LB, Kinoshita H, Gerard RD, Richardson JA, et al. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res. 2010; 107(2):294–304. Epub 2010/06/19. https://doi.org/10.1161/CIRCRESAHA.110.223172 PMID: 20558820; PubMed Central PMCID: PMC2921870.

30. Kuwahara K, Barrientos T, Pipes GC, Li S, Olson EN. Muscle-specific signaling mechanism that links actin dynamics to serum response factor. Molecular and cellular biology. 2005; 25(8):3173–81. Epub 2005/03/31. https://doi.org/10.1128/MCB.25.8.3173-3181.2005 PMID: 15798203; PubMed Central PMCID: PMC6517887.

31. Jain N, Vogel V. Spatial confinement downsizes the inflammatory response of macrophages. Nat Mater. 2018; 17(12):1134–44. Epub 2018/10/24. https://doi.org/10.1038/s41556-018-0190-6 PMID: 30349032; PubMed Central PMCID: PMC651903.

32. Chen Q, Huang J, Gong W, Chen Z, Huang J, Liu P, et al. MRTF-A-mediated FN and ICAM-1 expression in AGEs-induced rat glomerular mesangial cells via activating STAT5. Mol Cell Endocrinol. 2018; 460:123–33. Epub 2017/07/18. https://doi.org/10.1016/j.mce.2017.07.014 PMID: 28712960.

33. An J, Naruse TK, Hinohara K, Soejima Y, Sawabe M, Nakagawa Y, et al. MRTF-A regulates proliferation and survival properties of pro-atherogenic macrophages. J Mol Cell Cardiol. 2019; 133:26–35. Epub 2019/05/08. https://doi.org/10.1016/j.mccr.2019.05.015 PMID: 31128166.

34. Kong M, Chen X, Xu H, Wenpeng, Fang M, Xu H. Hepatocyte-specific deletion of Brg1 alleviates methionine-and-choline-deficient diet (MCD) induced non-alcoholic steatohepatitis in mice. Biochem Biophys Res Commun. 2018; 503(1):344–51. Epub 2018/06/12. https://doi.org/10.1016/j.bbrc.2018.06.027 PMID: 29890136.

35. Yu L, Weng X, Liang P, Dai X, Wu X, Xu H, et al. MRTF-A mediates LPS-induced pro-inflammatory transcription by interacting with the COMPASS complex. J Cell Sci. 2014; 127(Pt 21):4645–57. Epub 2014/09/06. https://doi.org/10.1242/jcs.152314 PMID: 25189621.

36. Wang D, Prakash J, Nguyen P, Davis-Dusenbury BN, Hill NS, Layne MD, et al. Bone morphogenetic protein signaling in vascular disease: anti-inflammatory action through myocardin-related transcription factor A. J Biol Chem. 2012; 287(33):28067–77. Epub 2012/06/22. https://doi.org/10.1074/jbc.M112.379487 PMID: 22718766; PubMed Central PMCID: PMC3431673.
39. Zheng WX, Cao XL, Wang F, Wang J, Ying TZ, Xiao W, et al. Baicalin inhibiting cerebral ischemia/hypoxia-induced neuronal apoptosis via MRTF-A-mediated transactivity. European journal of pharmacology. 2015; 767:201–10. Epub 2015/10/21. https://doi.org/10.1016/j.ejphar.2015.10.027 PMID: 26485504.

40. Cao XL, Hu XM, Hu JQ, Zheng WX. Myocardin-related transcription factor-A promoting neuronal survival against apoptosis induced by hypoxia/ischemia. Brain research. 2011; 1385:263–74. Epub 2011/02/22. https://doi.org/10.1016/j.brainres.2011.02.016 PMID: 2133636.

41. Zhong Z, Hu JQ, Wu XD, Sun Y, Jiang J. Anti-apoptotic effects of myocardin-related transcription factor-A on rat cardiomyocytes following hypoxia-induced injury. Canadian journal of physiology and pharmacology. 2016; 94(4):379–87. Epub 2016/02/09. https://doi.org/10.1139/cjpp-2014-0461 PMID: 2685486.

42. Xu Y, Luo Y, Wang ZY, Li X, Zheng P, Zhang TC. MRTF-A can activate Nrf2 to increase the resistance to doxorubicin. Oncotarget. 2017; 8(5):8436–46. Epub 2016/12/31. https://doi.org/10.18632/oncotarget.14246 PMID: 28035058; PubMed Central PMCID: PMC5352412.

43. Chen B, Li Z, Feng Y, Wu X, Xu Y. Myocardin-related transcription factor A (MRTF-A) mediates doxorubicin-induced PERP transcription in colon cancer cells. Biochem Biophys Res Commun. 2018; 503(3):1732–9. Epub 2018/08/07. https://doi.org/10.1016/j.bbrc.2018.07.106 PMID: 30078679.

44. Li S, Chang S, QI X, Richardson JA, Olson EN. Requirement of a myocardin-related transcription factor for development of mammary myoepithelial cells. Molecular and cellular biology. 2006; 26(15):5797–808. Epub 2006/07/19. https://doi.org/10.1128/MCB.00211-06 PMID: 16847332; PubMed Central PMCID: PMC1562772.

45. Cenik BK, Liu N, Chen B, Bezprozvannaya S, Olson EN, Bassel-Duby R. Myocardin-related transcription factors are required for skeletal muscle development. Development. 2016; 143(15):2853–61. Epub 2016/07/08. https://doi.org/10.1242/dev.135855 PMID: 27385017; PubMed Central PMCID: PMC5004908.

46. Mokalled MH, Johnson A, Kim Y, Oh J, Olson EN. Myocardin-related transcription factors regulate the Cdk5/P caret1 kinase cascade to control neurite outgrowth, neuronal migration and brain development. Development. 2010; 137(14):2365–74. Epub 2010/06/11. https://doi.org/10.1242/dev.047605 PMID: 20534669; PubMed Central PMCID: PMC2889604.

47. Nienaber CA, Clough RE. Management of acute aortic dissection. Lancet (London, England). 2015; 385(9970):800–11. Epub 2015/02/11. https://doi.org/10.1016/s0140-6736(14)61005-9 PMID: 25662791.

48. Zhong Z, Hu JQ, Wu XD, Sun Y, Jiang J. Myocardin-related transcription factor A overexpressing bone marrow stem cells protect cardiomyocytes and alleviate cardiac damage in a rat model of acute myocardial infarction. International journal of molecular medicine. 2015; 36(3):753–9. Epub 2015/07/03. https://doi.org/10.3892/ijmm.2015.2261 PMID: 26135208.

49. Zhao X, Ding EY, Yu OM, Xiang SY, Tan-Sah VP, Yung BS, et al. Induction of the matricellular protein CCN1 through RhoA and MRTF-A contributes to ischemic cardioprotection. J Mol Cell Cardiol. 2014; 75:152–61. Epub 2014/08/12. https://doi.org/10.1016/j.yjmcc.2014.07.017 PMID: 25106995; PubMed Central PMCID: PMC4157956.